HCW Biologics (HCWB) Competitors $5.59 +2.27 (+68.37%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.40 -0.19 (-3.38%) As of 09/12/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HCWB vs. RVPH, MAAQ, KZR, DARE, CASI, NEUP, ALLR, AKTX, TENX, and MIRAShould you be buying HCW Biologics stock or one of its competitors? The main competitors of HCW Biologics include Reviva Pharmaceuticals (RVPH), Mana Capital Acquisition (MAAQ), Kezar Life Sciences (KZR), Dare Bioscience (DARE), CASI Pharmaceuticals (CASI), Neuphoria Therapeutics (NEUP), Allarity Therapeutics (ALLR), Akari Therapeutics (AKTX), Tenax Therapeutics (TENX), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. HCW Biologics vs. Its Competitors Reviva Pharmaceuticals Mana Capital Acquisition Kezar Life Sciences Dare Bioscience CASI Pharmaceuticals Neuphoria Therapeutics Allarity Therapeutics Akari Therapeutics Tenax Therapeutics MIRA Pharmaceuticals HCW Biologics (NASDAQ:HCWB) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership. Do analysts rate HCWB or RVPH? HCW Biologics presently has a consensus target price of $35.00, indicating a potential upside of 526.12%. Reviva Pharmaceuticals has a consensus target price of $5.20, indicating a potential upside of 1,075.67%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than HCW Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Does the media refer more to HCWB or RVPH? In the previous week, HCW Biologics had 2 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 4 mentions for HCW Biologics and 2 mentions for Reviva Pharmaceuticals. HCW Biologics' average media sentiment score of 0.78 beat Reviva Pharmaceuticals' score of 0.59 indicating that HCW Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, HCWB or RVPH? Reviva Pharmaceuticals has lower revenue, but higher earnings than HCW Biologics. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHCW Biologics$2.57M4.68-$30.02M-$14.04-0.40Reviva PharmaceuticalsN/AN/A-$29.92M-$0.65-0.68 Is HCWB or RVPH more profitable? Reviva Pharmaceuticals has a net margin of 0.00% compared to HCW Biologics' net margin of -1,368.55%. Company Net Margins Return on Equity Return on Assets HCW Biologics-1,368.55% N/A -40.72% Reviva Pharmaceuticals N/A N/A -259.17% Which has more risk and volatility, HCWB or RVPH? HCW Biologics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500. Do institutionals & insiders have more ownership in HCWB or RVPH? 3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 42.7% of HCW Biologics shares are owned by insiders. Comparatively, 27.2% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryReviva Pharmaceuticals beats HCW Biologics on 8 of the 15 factors compared between the two stocks. Get HCW Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for HCWB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HCWB vs. The Competition Export to ExcelMetricHCW BiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.14M$3.20B$5.86B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-0.4021.1774.8625.97Price / Sales4.68438.17517.12182.33Price / CashN/A46.6837.5660.44Price / Book-0.929.6112.156.29Net Income-$30.02M-$53.29M$3.29B$270.96M7 Day Performance31.84%0.13%0.73%3.87%1 Month Performance24.50%5.61%4.82%4.87%1 Year Performance-77.09%10.49%60.58%26.12% HCW Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HCWBHCW Biologics2.0823 of 5 stars$5.59+68.4%$35.00+526.1%-75.5%$7.14M$2.57M-0.4040Short Interest ↑Gap UpHigh Trading VolumeRVPHReviva Pharmaceuticals3.0018 of 5 stars$0.450.0%$5.20+1,063.6%-60.5%$30.39MN/A-0.695MAAQMana Capital AcquisitionN/A$3.71+0.6%N/A+1,192.7%$30.14MN/A0.001KZRKezar Life Sciences3.8406 of 5 stars$4.02+0.2%$9.00+123.9%-30.3%$29.43M$7M-0.4160Positive NewsAnalyst UpgradeDAREDare Bioscience2.4524 of 5 stars$2.16+1.4%$10.00+363.0%-37.0%$29.12M-$17.70K-1.0130Short Interest ↓CASICASI Pharmaceuticals3.778 of 5 stars$2.34-0.4%$4.00+70.9%-68.4%$28.78M$28.54M-0.81180NEUPNeuphoria Therapeutics2.5846 of 5 stars$15.10+16.2%$21.00+39.1%N/A$28.39M$10K0.00N/ANews CoverageAnalyst ForecastALLRAllarity Therapeutics1.9605 of 5 stars$1.88flat$9.00+378.7%-42.4%$27.49MN/A0.0010Short Interest ↑AKTXAkari Therapeutics3.7363 of 5 stars$0.84-1.2%$3.30+292.8%-76.1%$27.40MN/A0.009Analyst ForecastShort Interest ↓TENXTenax Therapeutics2.271 of 5 stars$6.00-0.7%$18.00+200.0%+65.6%$27.38MN/A-6.529High Trading VolumeMIRAMIRA Pharmaceuticals2.9989 of 5 stars$1.41+2.2%$17.00+1,105.7%+8.2%$26.89MN/A-2.882News CoverageShort Interest ↓Gap Up Related Companies and Tools Related Companies Reviva Pharmaceuticals Competitors Mana Capital Acquisition Competitors Kezar Life Sciences Competitors Dare Bioscience Competitors CASI Pharmaceuticals Competitors Neuphoria Therapeutics Competitors Allarity Therapeutics Competitors Akari Therapeutics Competitors Tenax Therapeutics Competitors MIRA Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HCWB) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HCW Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HCW Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
